Free Trial
NASDAQ:ERAS

Erasca (ERAS) Stock Price, News & Analysis

Erasca logo
$2.61 -0.03 (-1.14%)
(As of 01:51 PM ET)

About Erasca Stock (NASDAQ:ERAS)

Key Stats

Today's Range
$2.51
$2.66
50-Day Range
$2.44
$3.18
52-Week Range
$1.51
$3.45
Volume
1.05 million shs
Average Volume
1.62 million shs
Market Capitalization
$737.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.08
Consensus Rating
Moderate Buy

Company Overview

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Erasca Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
56th Percentile Overall Score

ERAS MarketRank™: 

Erasca scored higher than 56% of companies evaluated by MarketBeat, and ranked 521st out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Erasca has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Erasca has only been the subject of 3 research reports in the past 90 days.

  • Read more about Erasca's stock forecast and price target.
  • Earnings Growth

    Earnings for Erasca are expected to grow in the coming year, from ($0.76) to ($0.64) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Erasca is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Erasca is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Erasca has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Erasca's valuation and earnings.
  • Percentage of Shares Shorted

    18.80% of the float of Erasca has been sold short.
  • Short Interest Ratio / Days to Cover

    Erasca has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Erasca has recently decreased by 2.17%, indicating that investor sentiment is improving.
  • Dividend Yield

    Erasca does not currently pay a dividend.

  • Dividend Growth

    Erasca does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    18.80% of the float of Erasca has been sold short.
  • Short Interest Ratio / Days to Cover

    Erasca has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Erasca has recently decreased by 2.17%, indicating that investor sentiment is improving.
  • News Sentiment

    Erasca has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Erasca this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for ERAS on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 2 people have added Erasca to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Erasca insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.50% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    67.78% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Erasca's insider trading history.
Receive ERAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter.

ERAS Stock News Headlines

HC Wainwright Has Positive Outlook of Erasca FY2024 Earnings
Jefferies Financial Group Initiates Coverage on Erasca (NASDAQ:ERAS)
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
Erasca initiated with a Buy at Jefferies
Bank of America Securities Sticks to Its Hold Rating for Erasca (ERAS)
Erasca (NASDAQ:ERAS) Receives "Buy" Rating from HC Wainwright
Erasca, Inc. Reports Strong Progress in Oncology Pipeline
See More Headlines

ERAS Stock Analysis - Frequently Asked Questions

Erasca's stock was trading at $2.13 at the beginning of the year. Since then, ERAS shares have increased by 22.1% and is now trading at $2.60.
View the best growth stocks for 2024 here
.

Erasca, Inc. (NASDAQ:ERAS) issued its earnings results on Tuesday, November, 12th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.06.

Erasca (ERAS) raised $262 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share.

Erasca's top institutional investors include Frazier Life Sciences Management L.P. (6.86%), State Street Corp (2.13%), PFM Health Sciences LP (1.73%) and Geode Capital Management LLC (1.59%). Insiders that own company stock include Jonathan E Lim, Bihua Chen, Alexander W Casdin and Valerie Denise Harding Start.
View institutional ownership trends
.

Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Erasca investors own include Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), American Water Works (AWK), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
11/12/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/26/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ERAS
Fax
N/A
Employees
126
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.08
High Stock Price Target
$8.00
Low Stock Price Target
$3.50
Potential Upside/Downside
+137.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-125,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.59 per share

Miscellaneous

Free Float
221,941,000
Market Cap
$723.79 million
Optionable
Optionable
Beta
1.16
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:ERAS) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners